Abstract
Background: Pharmacotherapy is of increasing interest in peripheral arterial disease (PAD), with novel therapies aiming at different factors contributing to the disease. For antiplatelet therapy, there is no unanimous agreement regarding the nature or duration of optimal antiplatelet therapy so as to reduce major adverse cardiovascular and limb-related events (e.g. repeat interventions and amputations). However, evidence on novel more potent antithrombotic agents, drug combinations and personalized antiplatelet therapy for PAD patients is accumulating. Similarly, statins are now considered as a standard of care in PAD patients, due to their multiple actions which include plaque stabilization, antiinflammatory properties and regression of atheroma.
Conclusion: This review focuses on current evidence available for various antiplatelet regimens and statin therapy for PAD and discusses future perspectives. We consider randomized controlled trials, together with the most important reviews and meta-analyses. Treatment algorithms based on currently available data.Keywords: Peripheral arterial disease, antiplatelet therapy, aspirin, statins, clopidogrel, cilostazol, ticagrelor.
Current Vascular Pharmacology
Title:Current Evidence and Future Perspectives on Anti-platelet and Statin Pharmacotherapy for Patients with Symptomatic Peripheral Arterial Disease
Volume: 15 Issue: 5
Author(s): Panagiotis Kitrou, Konstantinos Katsanos, Dimitris Karnabatidis, Lazaros Reppas, Elias Brountzos and Stavros Spiliopoulos*
Affiliation:
- Attiko University Hospital, 2nd Radiology Department, Division of Interventional Radiology, GR 12461, 1st Rimini St, Chaidari, Athens,Greece
Keywords: Peripheral arterial disease, antiplatelet therapy, aspirin, statins, clopidogrel, cilostazol, ticagrelor.
Abstract: Background: Pharmacotherapy is of increasing interest in peripheral arterial disease (PAD), with novel therapies aiming at different factors contributing to the disease. For antiplatelet therapy, there is no unanimous agreement regarding the nature or duration of optimal antiplatelet therapy so as to reduce major adverse cardiovascular and limb-related events (e.g. repeat interventions and amputations). However, evidence on novel more potent antithrombotic agents, drug combinations and personalized antiplatelet therapy for PAD patients is accumulating. Similarly, statins are now considered as a standard of care in PAD patients, due to their multiple actions which include plaque stabilization, antiinflammatory properties and regression of atheroma.
Conclusion: This review focuses on current evidence available for various antiplatelet regimens and statin therapy for PAD and discusses future perspectives. We consider randomized controlled trials, together with the most important reviews and meta-analyses. Treatment algorithms based on currently available data.Export Options
About this article
Cite this article as:
Kitrou Panagiotis , Katsanos Konstantinos , Karnabatidis Dimitris , Reppas Lazaros, Brountzos Elias and Spiliopoulos Stavros*, Current Evidence and Future Perspectives on Anti-platelet and Statin Pharmacotherapy for Patients with Symptomatic Peripheral Arterial Disease, Current Vascular Pharmacology 2017; 15 (5) . https://dx.doi.org/10.2174/1570161115666170504124911
DOI https://dx.doi.org/10.2174/1570161115666170504124911 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pathophysiological and Clinical Aspects of Iron Chelation Therapy in MDS
Current Pharmaceutical Design Estrogen(s) and Analogs as a Non-Immunogenic Endogenous Ligand in Targeted Drug/DNA Delivery
Current Medicinal Chemistry Prophylactic Vaccine Approach for Colon and Pancreatic Cancers: Present and Future
Current Medicinal Chemistry Antiarrhythmic Therapy on Prevention of Postoperative Atrial Fibrillation in Patients After Heart Surgery
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Modulation of Cardiovascular Function by Adipokines
Cardiovascular & Hematological Disorders-Drug Targets Weight Loss in Obesity and Metabolic Syndrome
Current Hypertension Reviews Optimized Turmeric Extracts have Potent Anti-Amyloidogenic Effects
Current Alzheimer Research From Early Origins. When and Why does Asthma Develop?
Current Pediatric Reviews Advances in Development of Phosphatidylinositol 3-Kinase Inhibitors
Current Medicinal Chemistry Synthetic Genomics and Synthetic Biology Applications Between Hopes and Concerns
Current Genomics Indications, Implications and Applications of Renal Denervation. Have we Discovered Something new?
Current Hypertension Reviews Use of Three-dimensional Printing in the Development of Optimal Cardiac CT Scanning Protocols
Current Medical Imaging Editorial (Novel Therapies and Botanical and Mechanical Approaches for Management of Cardiovascular Disease)
Recent Patents on Cardiovascular Drug Discovery Thrombomodulin Links Coagulation to Inflammation and Immunity
Current Drug Targets Gut Microbiota, Obesity and Bariatric Surgery: Current Knowledge and Future Perspectives
Current Pharmaceutical Design Stress and Vulnerability Due to the Care Task: An Observational Study on Older Caregivers
Current Psychopharmacology Perivascular Inflammation and Hypertensive Cardiovascular Remodeling
Current Hypertension Reviews Subject Index to Volume 1
Current Pharmacogenomics Novel Therapies for Schizophrenia: Understanding the Glutamatergic Synapse and Potential Targets for Altering N-methyl-D-aspartate Neurotransmission
Recent Patents on CNS Drug Discovery (Discontinued) Pharmacokinetics and Biotransformation of Tea Polyphenols
Current Drug Metabolism